Diagnosis of essential thrombocythaemia (ET) is challenging in patients lacking JAK2/CALR/MPL mutations. In a retrospective evaluation of 320 patients with 'triple-negative thrombocytosis', we assessed utility of bone marrow histology (90.9% of patients) and myeloid gene panel (MGP, 55.6%). Supportive histology ('myeloproliferative neoplasm-definite/probable', 36.8%) was associated with higher platelet counts and varied between centres. 14.6% MGP revealed significant variants: 3.4% JAK2/CALR/MPL and 11.2% other myeloid genes. Final clinical diagnosis was strongly predicted by histology, not MGP. 23.7% received cytoreduction (17.6% under 60 years). Real-world 'triple-negative' ET diagnosis currently depends heavily on histology; we advocate caution in MGP-negative cases and that specific guidelines are needed.
Journal article
2024-10-01T00:00:00+00:00
205
1411 - 1416
5
diagnosis, molecular, myeloproliferative, thrombocytosis, triple‐negative, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Calreticulin, Janus Kinase 2, Mutation, Receptors, Thrombopoietin, Retrospective Studies, Thrombocythemia, Essential, Thrombocytosis, United Kingdom